Niagen Bioscience, Inc.
NAGE
$6.76
$0.223.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 99.60M | 91.67M | 85.58M | 83.17M | 83.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.60M | 91.67M | 85.58M | 83.17M | 83.57M |
| Cost of Revenue | 38.01M | 35.34M | 33.53M | 32.45M | 32.79M |
| Gross Profit | 61.59M | 56.33M | 52.06M | 50.72M | 50.78M |
| SG&A Expenses | 47.84M | 50.02M | 48.55M | 49.22M | 51.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.87M | 91.22M | 87.89M | 87.53M | 89.17M |
| Operating Income | 7.73M | 447.00K | -2.30M | -4.36M | -5.60M |
| Income Before Tax | 8.86M | 1.49M | -1.35M | -3.53M | -4.94M |
| Income Tax Expenses | 305.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.55 | 1.49 | -1.35 | -3.53 | -4.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.55M | 1.49M | -1.35M | -3.53M | -4.94M |
| EBIT | 7.73M | 447.00K | -2.30M | -4.36M | -5.60M |
| EBITDA | 8.54M | 1.29M | -1.39M | -3.39M | -4.57M |
| EPS Basic | 0.11 | 0.02 | -0.02 | -0.05 | -0.07 |
| Normalized Basic EPS | 0.07 | 0.01 | -0.01 | -0.03 | -0.04 |
| EPS Diluted | 0.10 | 0.01 | -0.02 | -0.05 | -0.07 |
| Normalized Diluted EPS | 0.07 | 0.01 | -0.01 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 303.71M | 301.88M | 300.96M | 300.37M | 299.94M |
| Average Diluted Shares Outstanding | 310.24M | 303.69M | 300.97M | 300.38M | 299.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |